<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/290"/><api:result><api:object category="publication" id="290" last-affected-when="2024-03-17T08:55:54.597+00:00" last-modified-when="2024-03-17T08:55:54.597+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/290" created-when="2010-05-17T13:46:16.193+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-01-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2225605" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1023/A:1008386501738" last-modified-when="2022-09-11T05:45:00.42+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJF</api:initials><api:first-names>JJF</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008386501738"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1023/a:1008386501738</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>20</api:day><api:month>2</api:month><api:year>2020</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="3522731" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0032956195" last-modified-when="2022-07-12T17:24:19.303+01:00"><api:citation-count>91</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Background: Bisphosphonates are an important component of the treatment of metastatic bone disease but more potent, oral formulations are required to improve the effectiveness and convenience of treatment. An oral formulation of the new bisphosphonate, ibandronate (BM 21.0955) has recently been developed. Patients and methods: One hundred ten patients with bone metastases (77 breast, 16, prostate, 3 myeloma, 14 others) were recruited from a single institution to this double blind placebo-controlled evaluation of four oral dose levels (5, 10, 20 and 50 mg) of ibandronate. No changes in systemic anti-cancer treatment were allowed in the month before commencing treatment or during the study period. After an initial four-week tolerability phase, patients could continue on treatment for a luther three months without unblinding; patients initially allocated to placebo received ibandronate 50 mg. The primary endpoint was urinary calcium excretion (UCCR). Bone resorption was also assessed by measurement of pyridinoline (Pyr), deoxypyridinoline (Dpd), and the N-terminal (NTX) and C-terminal (Crosslaps) portions of the collagen crosslinking molecules. Results: Two patients did not receive any trial medication thus, 108 patients were evaluable for safety. Ninety-two patients were evaluable for efficacy. A dose dependent reduction was observed in both UCCR and collagen crosslink excretion. At the 50 mg dose level, the percentage reductions from baseline in UCCR, Pyr, Dpd, Crosslaps and NTX were 71%, 28%, 39% 80% and 74% respectively. One or more gastrointestinal (GI) adverse events occurring in the first month of treatment were reported by six (30%), seven (33%), nine (39%), nine (41%) and eleven (50%) patients at the placebo, 5, 10, 20 and 50 mg dose levels respectively. One patient (20 mg dose) developed radiographically confirmed oesophageal ulceration. GI tolerability may have been adversely affected by concommitant administration of non-steroidal antiinflammatory agents. Nine (8%) patients stopped treatment within the first month due to GI intolerability but these patients were evenly distributed across the five treatment groups. There was no difference in non-GI adverse events between groups. Conclusions: Oral ibandronate has potent effects on the rate of bone resorption at doses which are generally well tolerated. Further development is appropriate to evaluate the effects of long-term administration in the prevention of metastatic bone disease and the management of established skeletal metastases.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6602695566</api:identifier></api:identifiers></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57210456302</api:identifier></api:identifiers></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJF</api:initials><api:first-names>JJF</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name><api:first-name>F</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6602104827</api:identifier></api:identifiers></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Boehringer Mannheim Therapeutics</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="CH"><api:line type="organisation">F. Hoffmann-La Roche AG</api:line><api:line type="city">Basel</api:line><api:line type="country">Switzerland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">18341850000</api:identifier></api:identifiers></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Boehringer Mannheim Therapeutics</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="CH"><api:line type="organisation">F. Hoffmann-La Roche AG</api:line><api:line type="city">Basel</api:line><api:line type="country">Switzerland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">16947022100</api:identifier></api:identifiers></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Boehringer Mannheim Therapeutics</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="CH"><api:line type="organisation">F. Hoffmann-La Roche AG</api:line><api:line type="city">Basel</api:line><api:line type="country">Switzerland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7102324644</api:identifier></api:identifiers></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Hallamshire Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7102759272</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/A:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/A:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/A:1008386501738"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10355575</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="290" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10355575" last-modified-when="2020-04-29T00:25:50.42+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND: Bisphosphonates are an important component of the treatment of metastatic bone disease but more potent, oral formulations are required to improve the effectiveness and convenience of treatment. An oral formulation of the new bisphosphonate, ibandronate (BM 21.0955) has recently been developed. PATIENTS AND METHODS: One hundred ten patients with bone metastases (77 breast, 16, prostate, 3 myeloma, 14 others) were recruited from a single institution to this double blind placebo-controlled evaluation of four oral dose levels (5, 10, 20 and 50 mg) of ibandronate. No changes in systemic anti-cancer treatment were allowed in the month before commencing treatment or during the study period. After an initial four-week tolerability phase, patients could continue on treatment for a further three months without unblinding; patients initially allocated to placebo received ibandronate 50 mg. The primary endpoint was urinary calcium excretion (UCCR). Bone resorption was also assessed by measurement of pyridinoline (Pyr), deoxypyridinoline (Dpd), and the N-terminal (NTX) and C-terminal (Crosslaps) portions of the collagen crosslinking molecules. RESULTS: Two patients did not receive any trial medication thus, 108 patients were evaluable for safety. Ninety-two patients were evaluable for efficacy. A dose dependent reduction was observed in both UCCR and collagen crosslink excretion. At the 50 mg dose level, the percentage reductions from baseline in UCCR, Pyr, Dpd, Crosslaps and NTX were 71%, 28%, 39%, 80% and 74% respectively. One or more gastrointestinal (GI) adverse events occurring in the first month of treatment were reported by six (30%), seven (33%), nine (39%), nine (41%) and eleven (50%) patients at the placebo, 5, 10, 20 and 50 mg dose levels respectively. One patient (20 mg dose) developed radiographically confirmed oesophageal ulceration. GI tolerability may have been adversely affected by concomitant administration of non-steroidal anti-inflammatory agents. Nine (8%) patients stopped treatment within the first month due to GI intolerability but these patients were evenly distributed across the five treatment groups. There was no difference in non-GI adverse events between groups. CONCLUSIONS: Oral ibandronate has potent effects on the rate of bone resorption at doses which are generally well tolerated. Further development is appropriate to evaluate the effects of long-term administration in the prevention of metastatic bone disease and the management of established skeletal metastases.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJ</api:initials><api:first-names>JJ</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10355575</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008386501738"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Ann Oncol</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Analysis of Variance</api:keyword><api:keyword scheme="mesh">Area Under Curve</api:keyword><api:keyword scheme="mesh">Biomarkers</api:keyword><api:keyword scheme="mesh">Bone Neoplasms</api:keyword><api:keyword scheme="mesh">Bone Resorption</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh">Double-Blind Method</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Ibandronic Acid</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Prognosis</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword><api:keyword scheme="mesh">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh">Survival Rate</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0923-7534(19)57116-2</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>12</api:day><api:month>7</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Journal Article</api:item><api:item>Randomized Controlled Trial</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="873034" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10355575" last-modified-when="2023-01-31T23:48:27.393+00:00"><api:citation-count>52</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Background&lt;/h4&gt;Bisphosphonates are an important component of the treatment of metastatic bone disease but more potent, oral formulations are required to improve the effectiveness and convenience of treatment. An oral formulation of the new bisphosphonate, ibandronate (BM 21.0955) has recently been developed.&lt;h4&gt;Patients and methods&lt;/h4&gt;One hundred ten patients with bone metastases (77 breast, 16, prostate, 3 myeloma, 14 others) were recruited from a single institution to this double blind placebo-controlled evaluation of four oral dose levels (5, 10, 20 and 50 mg) of ibandronate. No changes in systemic anti-cancer treatment were allowed in the month before commencing treatment or during the study period. After an initial four-week tolerability phase, patients could continue on treatment for a further three months without unblinding; patients initially allocated to placebo received ibandronate 50 mg. The primary endpoint was urinary calcium excretion (UCCR). Bone resorption was also assessed by measurement of pyridinoline (Pyr), deoxypyridinoline (Dpd), and the N-terminal (NTX) and C-terminal (Crosslaps) portions of the collagen crosslinking molecules.&lt;h4&gt;Results&lt;/h4&gt;Two patients did not receive any trial medication thus, 108 patients were evaluable for safety. Ninety-two patients were evaluable for efficacy. A dose dependent reduction was observed in both UCCR and collagen crosslink excretion. At the 50 mg dose level, the percentage reductions from baseline in UCCR, Pyr, Dpd, Crosslaps and NTX were 71%, 28%, 39%, 80% and 74% respectively. One or more gastrointestinal (GI) adverse events occurring in the first month of treatment were reported by six (30%), seven (33%), nine (39%), nine (41%) and eleven (50%) patients at the placebo, 5, 10, 20 and 50 mg dose levels respectively. One patient (20 mg dose) developed radiographically confirmed oesophageal ulceration. GI tolerability may have been adversely affected by concomitant administration of non-steroidal anti-inflammatory agents. Nine (8%) patients stopped treatment within the first month due to GI intolerability but these patients were evenly distributed across the five treatment groups. There was no difference in non-GI adverse events between groups.&lt;h4&gt;Conclusions&lt;/h4&gt;Oral ibandronate has potent effects on the rate of bone resorption at doses which are generally well tolerated. Further development is appropriate to evaluate the effects of long-term administration in the prevention of metastatic bone disease and the management of established skeletal metastases.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJ</api:initials><api:first-names>JJ</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008386501738"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1569-8041</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10355575</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of oncology : official journal of the European Society for Medical Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Bone Neoplasms</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh">Bone Resorption</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Prognosis</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Survival Rate</api:keyword><api:keyword scheme="mesh">Analysis of Variance</api:keyword><api:keyword scheme="mesh">Area Under Curve</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword><api:keyword scheme="mesh">Double-Blind Method</api:keyword><api:keyword scheme="mesh">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Biomarkers</api:keyword><api:keyword scheme="mesh">Ibandronic Acid</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>4</api:day><api:month>6</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Randomized Controlled Trial</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="2921785" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1056303653" last-modified-when="2024-03-17T08:55:54.6+00:00"><api:citation-count>84</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>3</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0716614324.50</api:identifier></api:identifiers></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJF</api:initials><api:first-names>JJF</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name><api:first-name>F</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0602365724.96</api:identifier></api:identifiers></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="full">Boehringer Mannheim Therapeutics, Livingstone, Scotland and Mannheim, Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0727212205.93</api:identifier></api:identifiers></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="full">Boehringer Mannheim Therapeutics, Livingstone, Scotland and Mannheim, Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01032205411.03</api:identifier></api:identifiers></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="full">Boehringer Mannheim Therapeutics, Livingstone, Scotland and Mannheim, Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0646256476.57</api:identifier></api:identifiers></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Hallamshire Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0663427426.32</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008386501738"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10355575</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Prevention</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Analysis of Variance</api:keyword><api:keyword scheme="mesh">Area Under Curve</api:keyword><api:keyword scheme="mesh">Biomarkers</api:keyword><api:keyword scheme="mesh">Bone Neoplasms</api:keyword><api:keyword scheme="mesh">Bone Resorption</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Calcium</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh">Double-Blind Method</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Ibandronic Acid</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Prognosis</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword><api:keyword scheme="mesh">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh">Survival Rate</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Hybrid OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.68</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="240153" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000080380700013" last-modified-when="2024-03-14T05:35:43.09+00:00"><api:citation-count>72</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJF</api:initials><api:first-names>JJF</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000080380700013&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/A:1008386501738</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/A:1008386501738"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/A:1008386501738"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">197TA</api:identifier><api:identifier scheme="pubmed">10355575</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANNALS OF ONCOLOGY</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>bone resorption markers</api:keyword><api:keyword>ibandronate</api:keyword><api:keyword>metastatic bone disease</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="22813" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000080380700013" last-modified-when="2014-07-25T11:02:05.71+01:00"><api:citation-count>60</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Purohit</api:last-name><api:initials>OP</api:initials><api:first-names>OP</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Black</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinholes</api:last-name><api:initials>JJF</api:initials><api:first-names>JJF</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>J</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schlosser</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Huss</api:last-name><api:initials>H</api:initials><api:first-names>H</api:first-names><api:separate-first-names><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Quinn</api:last-name><api:initials>KJ</api:initials><api:first-names>KJ</api:first-names><api:separate-first-names><api:first-name>K</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kanis</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANN ONCOL</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>bone resorption markers</api:keyword><api:keyword>ibandronate</api:keyword><api:keyword>metastatic bone disease</api:keyword><api:keyword>MULTIPLE-MYELOMA</api:keyword><api:keyword>BREAST-CANCER</api:keyword><api:keyword>PAMIDRONATE</api:keyword><api:keyword>CLODRONATE</api:keyword><api:keyword>HYPERCALCEMIA</api:keyword><api:keyword>RESORPTION</api:keyword><api:keyword>TRIAL</api:keyword><api:keyword>MALIGNANCY</api:keyword><api:keyword>BISPHOSPHONATE</api:keyword><api:keyword>IMMUNOASSAY</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>311</api:begin-page><api:end-page>316</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Analysis of Variance</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Area Under Curve</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Biomarkers</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Bone Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Bone Resorption</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Double-Blind Method</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Ibandronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Prognosis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Prospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Survival Rate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Bone Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Bone Resorption</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Prognosis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Survival Rate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Analysis of Variance</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Area Under Curve</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Prospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Double-Blind Method</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Biomarkers</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Ibandronic Acid</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Prevention</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Analysis of Variance</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Area Under Curve</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Biomarkers</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Bone Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Bone Resorption</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Calcium</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Dose-Response Relationship, Drug</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Double-Blind Method</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Ibandronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Prognosis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Prospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Prostatic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Survival Rate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Treatment Outcome</api:keyword><api:keyword origin="record-data" source="wos-lite">bone resorption markers</api:keyword><api:keyword origin="record-data" source="wos-lite">ibandronate</api:keyword><api:keyword origin="record-data" source="wos-lite">metastatic bone disease</api:keyword><api:keyword origin="record-data" source="wos">bone resorption markers</api:keyword><api:keyword origin="record-data" source="wos">ibandronate</api:keyword><api:keyword origin="record-data" source="wos">metastatic bone disease</api:keyword><api:keyword origin="record-data" source="wos">MULTIPLE-MYELOMA</api:keyword><api:keyword origin="record-data" source="wos">BREAST-CANCER</api:keyword><api:keyword origin="record-data" source="wos">PAMIDRONATE</api:keyword><api:keyword origin="record-data" source="wos">CLODRONATE</api:keyword><api:keyword origin="record-data" source="wos">HYPERCALCEMIA</api:keyword><api:keyword origin="record-data" source="wos">RESORPTION</api:keyword><api:keyword origin="record-data" source="wos">TRIAL</api:keyword><api:keyword origin="record-data" source="wos">MALIGNANCY</api:keyword><api:keyword origin="record-data" source="wos">BISPHOSPHONATE</api:keyword><api:keyword origin="record-data" source="wos">IMMUNOASSAY</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3202 Clinical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0923-7534" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567" title="Annals of Oncology"><api:records><api:record source-name="summary"><api:title>Annals of Oncology</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/290/relationships"/></api:object></api:result></api:response>